Abbott Laboratories (ABT)
Market Price (12/23/2025): $125.25 | Market Cap: $218.2 BilSector: Health Care | Industry: Health Care Equipment
Abbott Laboratories (ABT)
Market Price (12/23/2025): $125.25Market Cap: $218.2 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.3%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.1% | Weak multi-year price returns2Y Excs Rtn is -25%, 3Y Excs Rtn is -54% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 25x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16%, CFO LTM is 9.1 Bil, FCF LTM is 6.9 Bil | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.6% | |
| Low stock price volatilityVol 12M is 22% | Key risksABT key risks include [1] significant product liability exposure from ongoing infant formula lawsuits, Show more. | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, Digital Health & Telemedicine, Aging Population & Chronic Disease, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.3%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.1% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16%, CFO LTM is 9.1 Bil, FCF LTM is 6.9 Bil |
| Low stock price volatilityVol 12M is 22% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, Digital Health & Telemedicine, Aging Population & Chronic Disease, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -25%, 3Y Excs Rtn is -54% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 25x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.6% |
| Key risksABT key risks include [1] significant product liability exposure from ongoing infant formula lawsuits, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Here are key points highlighting factors that have influenced Abbott Laboratories' (ABT) stock performance, based on recent information: 1. Weakness in Diagnostics Business: Declining revenue in Abbott's diagnostics segment has been a pivotal factor impacting its overall revenue figures.2. Underperformance in Nutrition Sales: The company has experienced lower-than-expected nutrition sales, including challenges in baby formula demand, contributing to investor uncertainty.
Show more
Stock Movement Drivers
Fundamental Drivers
The -8.0% change in ABT stock from 9/22/2025 to 12/22/2025 was primarily driven by a -8.0% change in the company's P/E Multiple.| 9222025 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 136.02 | 125.20 | -7.95% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 43109.00 | 43843.00 | 1.70% |
| Net Income Margin (%) | 32.43% | 31.88% | -1.69% |
| P/E Multiple | 16.96 | 15.61 | -8.01% |
| Shares Outstanding (Mil) | 1743.44 | 1742.14 | 0.07% |
| Cumulative Contribution | -7.95% |
Market Drivers
9/22/2025 to 12/22/2025| Return | Correlation | |
|---|---|---|
| ABT | -8.0% | |
| Market (SPY) | 2.7% | 4.9% |
| Sector (XLV) | 13.7% | 51.0% |
Fundamental Drivers
The -5.2% change in ABT stock from 6/23/2025 to 12/22/2025 was primarily driven by a -8.3% change in the company's P/E Multiple.| 6232025 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 132.08 | 125.20 | -5.21% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 42344.00 | 43843.00 | 3.54% |
| Net Income Margin (%) | 31.89% | 31.88% | -0.02% |
| P/E Multiple | 17.01 | 15.61 | -8.27% |
| Shares Outstanding (Mil) | 1739.21 | 1742.14 | -0.17% |
| Cumulative Contribution | -5.21% |
Market Drivers
6/23/2025 to 12/22/2025| Return | Correlation | |
|---|---|---|
| ABT | -5.2% | |
| Market (SPY) | 14.4% | 4.6% |
| Sector (XLV) | 18.0% | 42.9% |
Fundamental Drivers
The 11.7% change in ABT stock from 12/22/2024 to 12/22/2025 was primarily driven by a 127.8% change in the company's Net Income Margin (%).| 12222024 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 112.11 | 125.20 | 11.68% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 41217.00 | 43843.00 | 6.37% |
| Net Income Margin (%) | 13.99% | 31.88% | 127.85% |
| P/E Multiple | 33.81 | 15.61 | -53.85% |
| Shares Outstanding (Mil) | 1739.47 | 1742.14 | -0.15% |
| Cumulative Contribution | 11.68% |
Market Drivers
12/22/2024 to 12/22/2025| Return | Correlation | |
|---|---|---|
| ABT | 11.7% | |
| Market (SPY) | 16.9% | 20.7% |
| Sector (XLV) | 14.5% | 52.0% |
Fundamental Drivers
The 22.7% change in ABT stock from 12/23/2022 to 12/22/2025 was primarily driven by a 82.0% change in the company's Net Income Margin (%).| 12232022 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 102.05 | 125.20 | 22.69% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 45030.00 | 43843.00 | -2.64% |
| Net Income Margin (%) | 17.52% | 31.88% | 81.97% |
| P/E Multiple | 22.68 | 15.61 | -31.18% |
| Shares Outstanding (Mil) | 1752.97 | 1742.14 | 0.62% |
| Cumulative Contribution | 22.68% |
Market Drivers
12/23/2023 to 12/22/2025| Return | Correlation | |
|---|---|---|
| ABT | 19.3% | |
| Market (SPY) | 47.7% | 17.7% |
| Sector (XLV) | 18.4% | 51.2% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ABT Return | 28% | 31% | -21% | 2% | 5% | 13% | 61% |
| Peers Return | 17% | 22% | -9% | 4% | 10% | 18% | 76% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 113% |
Monthly Win Rates [3] | |||||||
| ABT Win Rate | 67% | 58% | 42% | 50% | 58% | 58% | |
| Peers Win Rate | 57% | 60% | 47% | 52% | 53% | 57% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| ABT Max Drawdown | -27% | -3% | -31% | -16% | -8% | -1% | |
| Peers Max Drawdown | -29% | -6% | -21% | -14% | -4% | -10% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: JNJ, MDT, TMO, DHR, BSX. See ABT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/22/2025 (YTD)
How Low Can It Go
| Event | ABT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -36.2% | -25.4% |
| % Gain to Breakeven | 56.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -31.6% | -33.9% |
| % Gain to Breakeven | 46.2% | 51.3% |
| Time to Breakeven | 24 days | 148 days |
| 2018 Correction | ||
| % Loss | -11.7% | -19.8% |
| % Gain to Breakeven | 13.3% | 24.7% |
| Time to Breakeven | 50 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -30.6% | -56.8% |
| % Gain to Breakeven | 44.1% | 131.3% |
| Time to Breakeven | 1,053 days | 1,480 days |
Compare to
In The Past
Abbott Laboratories's stock fell -36.2% during the 2022 Inflation Shock from a high on 12/27/2021. A -36.2% loss requires a 56.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
AI Analysis | Feedback
Johnson & Johnson, but specializing in medical devices, diagnostics, and nutrition.
Medtronic for medical devices and diagnostics, plus a major nutrition business.
AI Analysis | Feedback
- Nutritional Products: Science-based nutrition products for infants, children, and adults, including brands like Similac, Ensure, and Pedialyte.
- Diagnostic Products: Systems and tests used for rapid and accurate disease detection, screening, and monitoring, such as the Alinity and ID NOW platforms.
- Medical Devices: A broad portfolio of cardiovascular, neuromodulation, and diabetes care technologies, including FreeStyle Libre continuous glucose monitors, pacemakers, and MitraClip.
- Established Pharmaceuticals: A portfolio of branded generic drugs, primarily marketed in emerging markets, addressing therapeutic areas like gastroenterology, women's health, and respiratory care.
AI Analysis | Feedback
Abbott Laboratories (ABT) primarily sells its products to other companies and institutions within the healthcare sector, rather than directly to individual consumers. Its extensive portfolio of medical devices, diagnostics, nutritional products, and established pharmaceuticals is distributed through various channels.
Major customer companies for Abbott include large healthcare distributors, which serve as key intermediaries by purchasing products in bulk and then supplying them to a vast network of healthcare providers. While Abbott does not publicly disclose specific individual customer names due to the competitive and fragmented nature of the healthcare market, the following are prominent healthcare distributors that would likely be major customers:
- McKesson Corporation (MCK)
- Cencora (formerly AmerisourceBergen Corporation) (COR)
- Cardinal Health, Inc. (CAH)
Beyond these distributors, Abbott also sells directly to various healthcare entities globally, including large hospital systems, retail pharmacy chains, and laboratory networks.
AI Analysis | Feedback
null
AI Analysis | Feedback
Robert B. Ford, Chairman of the Board and Chief Executive Officer
Mr. Ford joined Abbott in 1996, starting his career in the diabetes care business. He has held numerous leadership positions across Abbott's medical device, nutrition, and diabetes care businesses. As Executive Vice President of Medical Devices, he oversaw the integration of St. Jude Medical in 2017, which was Abbott's largest acquisition at the time. He was appointed President and Chief Operating Officer in October 2018 before becoming Chief Executive Officer on March 31, 2020. In December 2021, he was also elected Chairman of the Board. During the COVID-19 pandemic, Mr. Ford led the company's efforts in developing and distributing COVID-19 tests.
Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer
Mr. Boudreau began his career at Abbott in 1997. He has served in various finance and controller roles across Abbott's Diagnostics, Diabetes Care, Nutrition, and Medical Devices businesses. These roles include Divisional Vice President, Controller, Medical Devices from 2017 to 2020, and Vice President, Controller since 2020. He became a corporate officer in 2020. Mr. Boudreau was appointed Executive Vice President, Finance and Chief Financial Officer in July 2024.
Elizabeth Cushman, Executive Vice President, General Counsel and Secretary
Lisa D. Earnhardt, Executive Vice President and Group President, Medical Devices
Joseph Manning, Executive Vice President, Nutritional Products
AI Analysis | Feedback
The key risks to Abbott Laboratories (ABT) include:
- Regulatory and Legal Challenges: Abbott operates in a highly regulated environment, and changes in healthcare regulatory requirements can adversely affect demand and pricing for its products. The company also faces significant risks related to product liability claims, such as the ongoing lawsuits concerning infant formula, and potential product recalls. Furthermore, maintaining and protecting intellectual property is crucial, and any infringement or loss of patent protection could lead to substantial losses.
- Supply Chain and Manufacturing Disruptions: As a global healthcare company, Abbott relies on a large and complex supply chain. Disruptions to this supply chain, including manufacturing problems, could negatively affect the company's operations, revenues, and profitability. Issues related to product quality and compliance with manufacturing standards also pose risks of recalls and damage to brand reputation.
- Market and Pricing Pressures: Abbott is exposed to various market and economic pressures, including government-imposed pricing controls, such as the Volume-Based Procurement (VBP) program in China, which can lead to significant price cuts on medical products. Intense competition and the rapid obsolescence of products due to technological innovation by competitors also pose a risk to the company's market share and profitability. Additionally, fluctuations in foreign currency exchange rates can adversely affect Abbott's financial results, as a significant portion of its revenues and costs are realized in other currencies. The expected decline in COVID-19 testing revenue in 2025 is another specific financial headwind.
AI Analysis | Feedback
The primary clear emerging threat to Abbott Laboratories is the potential for **non-invasive continuous glucose monitoring (CGM) technologies** to disrupt its highly successful FreeStyle Libre product line.
While still in development by various tech giants and startups, these emerging technologies aim to provide glucose readings without the need for skin-piercing sensors, offering greater convenience and potentially lower cost. A breakthrough in this area would fundamentally challenge Abbott's significant market position in diabetes care, similar to how smartphones disrupted feature phones.
Another emerging threat comes from the rise of **personalized nutrition platforms**. These platforms leverage genetic, microbiome, and lifestyle data to offer highly customized dietary advice and supplements. This trend could gradually erode the market share of Abbott's mass-market nutritional products (such as Ensure and Glucerna) by offering solutions perceived as more effective and tailored to individual needs.
AI Analysis | Feedback
Abbott Laboratories (ABT) operates in several key healthcare markets globally. The addressable markets for its main products and services are sized as follows:
Medical Devices
- Overall Medical Devices: Abbott's medical devices segment generated $19 billion in sales for 2024, representing 45% of the company's total revenue.
- Diabetes Care Devices: The global diabetes care devices market was estimated at USD 65.74 billion in 2025 and is expected to reach USD 91.95 billion by 2030. Another source valued the global market at USD 53.5 billion in 2024, projected to grow to USD 167.5 billion by 2034.
- Cardiovascular Devices: The global cardiovascular devices market was estimated at USD 77.71 billion in 2024 and is projected to reach USD 110.39 billion by 2029. Other estimates for 2024 include USD 53.7 billion, USD 57.35 billion, and USD 62.3 billion.
Diagnostics
- Overall Diagnostics: The global diagnostics market is approximated to be worth US$40–45 billion, with point-of-care (POC) diagnostics contributing US$12–13 billion. The global clinical diagnostics market size was estimated at USD 115.51 billion in 2024 and is anticipated to reach USD 169.23 billion by 2030. Another source estimates the clinical diagnostics market to reach USD 88.79 billion in 2025 and USD 115.94 billion by 2030.
- Molecular Diagnostics: The global molecular diagnostics market was valued at USD 27 billion in 2024 and is projected to grow to USD 40.4 billion by 2034.
- Immunoassay: The global immunoassay market is projected to reach USD 47.7 billion by 2030 from USD 35.5 billion in 2025.
Nutritional Products
- Overall Nutritional Products: Abbott's nutritional products accounted for 22% of its 2024 revenues.
- Pediatric Nutrition: The global pediatric nutrition market was valued at USD 94.8 billion in 2024 and is expected to reach USD 182.4 billion by 2034. Other estimates for 2024 include USD 3.9 billion, projected to reach USD 5.3 billion by 2034, and USD 4.49 billion in 2025, expected to reach USD 6.93 billion by 2032.
- Adult Clinical Nutrition: The global adult clinical nutrition market size was estimated at USD 21.56 billion in 2024 and is predicted to increase to approximately USD 34.82 billion by 2034. The adult segment dominated the overall clinical nutrition market in 2024 with a 73.7% share.
Established Pharmaceutical Products (outside the U.S.)
- Branded Generics: Abbott's Established Pharmaceuticals Division (EPD) focuses on branded generic pharmaceuticals sold outside the United States. The global branded generics market size was estimated at USD 263.08 billion in 2024 and is projected to reach USD 431.43 billion by 2033. Other estimates for the global branded generics market include USD 368.52 billion in 2024, expected to reach USD 683.63 billion by 2032, and USD 261.41 billion in 2024, expected to reach USD 375.90 billion by 2030.
AI Analysis | Feedback
Abbott Laboratories (ABT) is expected to drive future revenue growth over the next 2-3 years through several key strategies and market dynamics:
- Innovation and New Product Launches in Medical Devices: A primary driver of growth is expected to come from Abbott's robust pipeline and recent innovations in its Medical Devices segment, particularly in Diabetes Care and Electrophysiology. The continued success and expansion of products like the FreeStyle Libre continuous glucose monitoring system and the anticipated launch and rollout of electrophysiology devices such as the Volt PFA system are significant contributors. Abbott announced more than 15 new growth opportunities from its R&D pipeline in 2024, indicating a sustained focus on product innovation.
- Strong Performance and Expansion in Adult Nutrition: The Adult Nutrition business, led by market-leading brands such as Ensure and Glucerna, consistently delivers solid growth. This segment benefits from favorable demographic trends and increasing focus on protein intake and immune system health.
- Growth in Established Pharmaceutical Products (EPD) and Biosimilars: Abbott's Established Pharmaceutical Products (EPD) segment is experiencing high single-digit growth, particularly in key international markets. The company also highlights biosimilars launches as a key strategic growth pillar, which are expected to contribute to future revenue.
- Strategic International and Emerging Market Expansion: Abbott's global diversified business model, with approximately 60% of sales generated outside the United States, positions it well for growth in international markets. Expansion efforts and increasing healthcare access in key emerging markets like India, China, Latin America, and the Middle East are expected to fuel robust growth across various segments.
AI Analysis | Feedback
Share Repurchases
- Abbott's board of directors authorized a new share repurchase program of up to $7 billion in October 2024.
- In December 2021, the board authorized a share repurchase program of up to $5 billion, which was in addition to the unused portion of a $3 billion program authorized in October 2019.
- The company's annual share buybacks were $1.295 billion in 2024, $1.227 billion in 2023, and $3.795 billion in 2022.
Outbound Investments
- On April 27, 2023, Abbott acquired Cardiovascular Systems, Inc. (CSI) for $851 million to enhance its portfolio of vascular device offerings.
- On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. to further its efforts in developing connected solutions for diabetes management.
- In September 2021, Abbott acquired Walk Vascular, a company specializing in thrombectomy systems for treating blood clots.
Capital Expenditures
- Abbott's capital expenditures were approximately $2.207 billion in 2024, $2.202 billion in 2023, and $1.777 billion in 2022.
- These expenditures were primarily focused on upgrading and expanding manufacturing and research and development facilities and equipment, investing in information technology, and placing laboratory instruments with customers.
- Expected capital expenditures for 2025 are projected to be around $2.372 billion.
Latest Trefis Analyses
Trade Ideas
Select ideas related to ABT. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 17.4% | 17.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.9% | 10.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.7% | 2.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.4% | 11.4% | -5.1% |
| 09302022 | ABT | Abbott Laboratories | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 5.6% | 2.0% | -1.3% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Abbott Laboratories
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 166.26 |
| Mkt Cap | 189.8 |
| Rev LTM | 39,246 |
| Op Inc LTM | 7,216 |
| FCF LTM | 5,658 |
| FCF 3Y Avg | 5,789 |
| CFO LTM | 7,382 |
| CFO 3Y Avg | 7,515 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 1.9% |
| Rev Chg Q | 6.7% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Mgn LTM | 19.1% |
| Op Mgn 3Y Avg | 18.3% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 22.4% |
| CFO/Rev 3Y Avg | 19.9% |
| FCF/Rev LTM | 17.3% |
| FCF/Rev 3Y Avg | 15.3% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Medical Devices | 16,887 | 14,802 | 14,367 | 11,787 | 12,239 |
| Diagnostics | 9,988 | 16,469 | 15,644 | 10,805 | 7,713 |
| Nutritionals | 8,154 | 7,459 | 8,294 | 7,647 | 7,409 |
| Established Pharmaceutical | 5,066 | 4,912 | 4,718 | 4,303 | 4,486 |
| Other | 14 | 11 | 52 | 66 | 57 |
| Total | 40,109 | 43,653 | 43,075 | 34,608 | 31,904 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Medical Devices | 5,306 | 4,436 | 4,514 | 3,038 | 3,769 |
| Diagnostics | 2,433 | 6,640 | 6,256 | 3,725 | 1,912 |
| Nutritionals | 1,333 | 706 | 1,763 | 1,751 | 1,705 |
| Established Pharmaceutical | 1,206 | 1,049 | 889 | 794 | 904 |
| Total | 10,278 | 12,831 | 13,422 | 9,308 | 8,290 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Goodwill and intangible assets | 32,494 | 33,253 | 35,970 | 38,528 | 40,220 |
| Medical Devices | 9,029 | 7,844 | 7,261 | 6,893 | 6,640 |
| All other | 8,458 | 7,912 | 6,987 | 5,096 | 4,637 |
| Cash and investments | 8,078 | 10,936 | 11,065 | 7,969 | 5,023 |
| Diagnostics | 7,767 | 7,985 | 7,699 | 7,696 | 5,235 |
| Nutritionals | 4,270 | 3,625 | 3,425 | 3,478 | 3,274 |
| Established Pharmaceutical | 3,118 | 2,883 | 2,789 | 2,888 | 2,858 |
| Total | 73,214 | 74,438 | 75,196 | 72,548 | 67,887 |
Price Behavior
Price Behavior
| Market Price | $125.20 | |
| Market Cap ($ Bil) | 218.1 | |
| First Trading Date | 04/06/1983 | |
| Distance from 52W High | -9.5% | |
| 50 Days | 200 Days | |
| DMA Price | $126.71 | $129.47 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -1.2% | -3.3% |
| 3M | 1YR | |
| Volatility | 18.5% | 22.3% |
| Downside Capture | 22.79 | 7.04 |
| Upside Capture | -20.45 | 16.72 |
| Correlation (SPY) | 5.2% | 21.2% |
ABT Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.09 | 0.08 | 0.16 | 0.11 | 0.24 | 0.34 |
| Up Beta | -0.01 | 0.32 | 0.45 | 0.49 | 0.23 | 0.36 |
| Down Beta | 0.79 | 0.27 | 0.34 | 0.30 | 0.45 | 0.42 |
| Up Capture | 27% | -19% | -8% | -9% | 10% | 8% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 11 | 20 | 32 | 67 | 135 | 388 |
| Down Capture | -15% | 5% | 6% | -9% | 10% | 51% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 8 | 21 | 30 | 58 | 113 | 361 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of ABT With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| ABT | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 12.6% | 13.6% | 14.7% | 67.3% | 6.8% | -0.5% | -16.6% |
| Annualized Volatility | 22.2% | 17.3% | 19.7% | 19.3% | 15.2% | 17.6% | 35.4% |
| Sharpe Ratio | 0.45 | 0.57 | 0.57 | 2.54 | 0.23 | -0.18 | -0.25 |
| Correlation With Other Assets | 52.2% | 21.6% | 11.0% | -4.0% | 46.4% | -3.9% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of ABT With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| ABT | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 5.1% | 8.7% | 15.0% | 18.9% | 11.8% | 5.1% | 35.8% |
| Annualized Volatility | 21.7% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.9% |
| Sharpe Ratio | 0.19 | 0.42 | 0.71 | 0.98 | 0.51 | 0.18 | 0.63 |
| Correlation With Other Assets | 63.4% | 42.8% | 9.4% | -0.5% | 46.1% | 15.0% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of ABT With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| ABT | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 12.9% | 10.0% | 14.9% | 14.9% | 6.7% | 5.5% | 69.9% |
| Annualized Volatility | 23.6% | 16.7% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.52 | 0.50 | 0.71 | 0.84 | 0.30 | 0.23 | 0.90 |
| Correlation With Other Assets | 73.3% | 58.4% | 4.1% | 11.9% | 47.8% | 11.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/15/2025 | -2.9% | -4.3% | -3.3% |
| 7/17/2025 | -8.5% | -4.5% | -1.9% |
| 4/16/2025 | 2.8% | 2.9% | 5.6% |
| 1/22/2025 | 0.8% | 9.1% | 14.0% |
| 10/16/2024 | 1.5% | 0.1% | -0.3% |
| 7/18/2024 | -4.4% | 2.5% | 6.0% |
| 4/17/2024 | -3.0% | -1.5% | -4.2% |
| 1/24/2024 | -2.8% | -0.5% | 4.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 14 | 13 |
| # Negative | 14 | 10 | 11 |
| Median Positive | 3.0% | 3.4% | 5.6% |
| Median Negative | -2.7% | -1.7% | -3.3% |
| Max Positive | 7.8% | 9.1% | 14.0% |
| Max Negative | -8.5% | -6.7% | -8.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 10292025 | 10-Q 9/30/2025 |
| 6302025 | 7302025 | 10-Q 6/30/2025 |
| 3312025 | 4302025 | 10-Q 3/31/2025 |
| 12312024 | 2212025 | 10-K 12/31/2024 |
| 9302024 | 10312024 | 10-Q 9/30/2024 |
| 6302024 | 7312024 | 10-Q 6/30/2024 |
| 3312024 | 5022024 | 10-Q 3/31/2024 |
| 12312023 | 2162024 | 10-K 12/31/2023 |
| 9302023 | 11012023 | 10-Q 9/30/2023 |
| 6302023 | 8032023 | 10-Q 6/30/2023 |
| 3312023 | 5042023 | 10-Q 3/31/2023 |
| 12312022 | 2172023 | 10-K 12/31/2022 |
| 9302022 | 11012022 | 10-Q 9/30/2022 |
| 6302022 | 8022022 | 10-Q 6/30/2022 |
| 3312022 | 5032022 | 10-Q 3/31/2022 |
| 12312021 | 2182022 | 10-K 12/31/2021 |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | Shroff Eric | Senior Vice President | 11252025 | Sell | 128.02 | 1,586 | 203,043 | 3,889,814 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.